Pay in 4 interest-free payments of $6.93 Learn more
Ships within 48 hours · Estimated delivery Aug 18 - Aug 23
Why is the UK market expanding
An approved antidiabetic treatment due to its hypoglycemic effects, it is of further clinical interest as an appetite suppressant and weight loss agent, indicated for chronic weight management in non-diabetic obese and overweight patients
At 2 mg per injection, you average roughly 3.5 injections per week for approximately 7 mg
Obesity is the driver of many chronic diseases, and treating it with GLP-1s will help reduce long-term obesity-related complications and healthcare costs, she describes
Liraglutide as adjunct to insulin treatment in type 1 diabetes does not interfere with glycaemic recovery or gastric emptying rate during hypoglycaemia: a randomized, placebo-controlled, double-blind, parallel-group study
A.SmithB
US$ 20.08
US$ 26.57
US$ 26.97
US$ 23.83
